Researchers have developed miniature models of the carotid artery that can predict individual stroke risk by capturing how blood flows through a person's specific vessel geometry. These "arteries-on-a-chip" represent a significant advance in personalized medicine, moving stroke prediction beyond generic population studies.
The models recreate the carotid artery, the major vessel supplying blood to the brain. By using patient-specific imaging data, scientists can construct chips that replicate each person's unique artery shape and size. Blood flow patterns through these customized channels reveal where dangerous clots are most likely to form.
Traditional stroke risk assessment relies on population-level data and general markers like blood pressure or cholesterol levels. These approaches miss the anatomical variations that determine whether blood will flow smoothly or create problematic eddies where clots can develop. The chip technology addresses this gap by showing how individual arterial geometry influences clot formation risk.
The research builds on microfluidics technology, where researchers create tiny channels that mimic biological structures. Previous studies demonstrated that channel shape dramatically affects blood clotting behavior. By scaling this principle to patient-specific carotid artery models, scientists can now test how each person's actual vessel architecture influences stroke danger.
The implications extend beyond prediction. Once a chip reveals elevated clot risk in a particular person's artery, doctors could test whether interventions like anticoagulant medications or lifestyle changes reduce that risk before the patient ever experiences a stroke. This enables preventive medicine tailored to individual physiology rather than broad populations.
Limitations remain. The chips currently model only the mechanical blood flow aspects of stroke risk. They do not yet fully incorporate the complex biological factors that influence clotting, including inflammation markers or genetic predispositions. Additionally, manufacturing personalized chips for every at-risk patient requires scaling up production and reducing costs.
Researchers acknowledge that clinical validation